![]() |
|
|
Vol. 296, Issue 2, 270-275, February 2001
Department of Applied Pharmacology, Faculty of Pharmaceutical
Sciences (I.T., H.N., Y.K.) and Department of Virology, Faculty of
Medicine (K.S.), Toyama Medical and Pharmaceutical University, Toyama,
Japan; and National Heart, Lung, and Blood Institute, National
Institute of Health, Bethesda, Maryland (T.A.)
The effects of systemic and local injections of gabapentin, a novel
anticonvulsant agent, were tested on nociceptive behaviors in mice with
acute herpetic pain. Transdermal infection with herpes simplex virus
type-1 (HSV-1) produced nociceptive hypersensitivity of the infected
hind paw to innocuous (allodynia) and noxious mechanical stimulation
(hyperalgesia) with von Frey filaments. Systemic administration of
gabapentin (10-100 mg/kg, peroral) produced a dose-dependent
inhibition of both allodynia and hyperalgesia; gabapentin (30-300
mg/kg) did not affect locomotor activity. Intrathecal injection of
gabapentin (10-100 µg/animal) also attenuated dose dependently both
nociceptive hypersensitivities. In contrast, intraplantar,
intracisternal, and intracerebroventricular administration of
gabapentin (10-100 µg/animal) had no effect on the HSV-1-induced nociceptive hypersensitivities. Pretreatment with naltrexone (1 mg/kg)
inhibited antinociceptive effect of morphine (5 mg/kg), but not
gabapentin (100 mg/kg). Repeated administration of morphine (5 mg/kg,
four times) led to tolerance of antinociceptive action, whereas
gabapentin (100 mg/kg, four times) had antinociceptive effect even
after the forth administration. The present results suggest that
gabapentin is effective in the treatment of acute herpetic pain without
apparent adverse effects, and analgesic action of gabapentin is mainly
mediated by actions on the spinal cord.
This article has been cited by other articles:
![]() |
C. Hansen, I. Gilron, and M. Hong The Effects of Intrathecal Gabapentin on Spinal Morphine Tolerance in the Rat Tail-Flick and Paw Pressure Tests Anesth. Analg., October 1, 2004; 99(4): 1180 - 1184. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Takasaki, T. Suzuki, A. Sasaki, K. Nakao, M. Hirakata, K. Okano, T. Tanaka, H. Nagase, K. Shiraki, H. Nojima, et al. Suppression of Acute Herpetic Pain-Related Responses by the {kappa}-Opioid Receptor Agonist (-)-17-Cyclopropylmethyl-3,14{beta}-dihydroxy-4,5{alpha}-epoxy-6{beta}-[N-methyl-3-trans-3-(3-furyl) Acrylamido] Morphinan Hydrochloride (TRK-820) in Mice J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 36 - 41. [Abstract] [Full Text] |
||||